KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Convertible Debt: 2010-2024

Historic Convertible Debt for Pacira BioSciences (PCRX) over the last 12 years, with Dec 2024 value amounting to $279.3 million.

  • Pacira BioSciences' Convertible Debt fell 41.56% to $280.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $280.3 million, marking a year-over-year decrease of 41.56%. This contributed to the annual value of $279.3 million for FY2024, which is 29.92% down from last year.
  • Per Pacira BioSciences' latest filing, its Convertible Debt stood at $279.3 million for FY2024, which was down 29.92% from $398.6 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Convertible Debt registered a high of $404.8 million during FY2022, and its lowest value of $279.3 million during FY2024.
  • Moreover, its 3-year median value for Convertible Debt was $398.6 million (2023), whereas its average is $360.9 million.
  • Per our database at Business Quant, Pacira BioSciences' Convertible Debt grew by 19.31% in 2022 and then dropped by 29.92% in 2024.
  • Yearly analysis of 5 years shows Pacira BioSciences' Convertible Debt stood at $313.0 million in 2020, then climbed by 8.38% to $339.3 million in 2021, then climbed by 19.31% to $404.8 million in 2022, then dropped by 1.53% to $398.6 million in 2023, then decreased by 29.92% to $279.3 million in 2024.